Entera Bio Ltd. Appoints Riccardo P. Camisasca as Chief Medical Officer

What Happened

• On August 18, 2026, Entera Bio Ltd. issued a press release announcing the appointment of Dr. Riccardo Paolo Camisasca as the company’s Chief Medical Officer. The disclosure was made under Regulation FD and furnished as Exhibit 99.1 to the Current Report on Form 8-K filed the same day.

Key Details

• Appointment announced: August 18, 2026.
• Executive named: Dr. Riccardo Paolo Camisasca — appointed Chief Medical Officer.
• Disclosure type: Regulation FD disclosure; press release furnished as Exhibit 99.1 to the Form 8-K.
• Filing accession: Current Report on Form 8-K filed August 18, 2026 (Accession 0001178913-26-004178).

Why It Matters

• A Chief Medical Officer provides clinical and regulatory leadership; this appointment identifies who will oversee Entera Bio’s medical and development strategy going forward.
• The filing is a formal, public disclosure of the executive change and makes the press release available to investors and the market for review.